Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | terminated | Phase 2 | 4 | Indiana UniversityOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03856099 | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02663271 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | terminated | Phase 2 | 10 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT04460495 | Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI | terminated | N/A | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02163356 | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma(SPOC2013-001) | terminated | Phase 1 | 4 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01925573 | Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | terminated | N/A | 7 | University of Maryland, BaltimoreOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | terminated | Phase 1 | 4 | Klinikum StuttgartOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02212574 | Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma | terminated | Early Phase 1 | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | terminated | Phase 1 | 3 | Washington University School of MedicineOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT01587144 | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | terminated | Phase 2 | 18 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Oct 19, 2021 | clinicaltrials |
| NCT01058850 | Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas | terminated | Phase 1 | 3 | Paul Graham FisherOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03861598 | Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells | terminated | Early Phase 1 | 4 | West Virginia UniversityOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma(FORWARD) | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects(INTACT) | terminated | Phase 3 | 19 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 22, 2021 | clinicaltrials |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery | terminated | Phase 2 | 8 | Oslo University HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | terminated | Phase 1 / Phase 2 | 14 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | terminated | Phase 2 | 3 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01583842 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | terminated | Early Phase 1 | 10 | Miguel PampaloniOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | terminated | Phase 3 | 40 | AbbVieINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | terminated | Phase 1 | 2 | Gary Archer Ph.D.OTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02340156 | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | terminated | Phase 2 | 1 | SynerGene Therapeutics, Inc.INDUSTRY | 2 | Mar 3, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT00592865 | Risk Factors for Adult-Onset Brain Tumors | terminated | — | 850 | Vanderbilt University Medical CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | terminated | Phase 2 | 21 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | terminated | Phase 2 | 12 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | terminated | Phase 2 | 4 | Jean M. Tersak, M.D.OTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT01987596 | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer | terminated | Phase 3 | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03151772 | Bioavailability of Disulfiram and Metformin in Glioblastomas(INSIDE) | terminated | Early Phase 1 | 3 | Sahlgrenska University HospitalOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT00698009 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01466855 | A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma(IARB1) | terminated | Early Phase 1 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03115138 | Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.(Bi-GLAM) | terminated | N/A | 19 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02116959 | Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma | terminated | Phase 1 | 6 | University of California, San FranciscoOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02855086 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery | terminated | Phase 1 / Phase 2 | 3 | Eben RosenthalOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | terminated | Phase 1 | 65 | Tocagen Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01400672 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | terminated | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Oct 6, 2022source: clinicaltrials